"phase_id","region","country","location","sampleType","startDate","endDate","midpointDate","testTime","testName","citationID","nSeropositives","nSamples","sensitivityMean","sensitivityL","sensitivityH","includedTable","notes","timeKnown","antigenTarget","antibodyTarget","technique","design"
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Abbott Alinity i SARS-CoV-2 IgG nucleocapsid","n-225",149,185,80.54,74.09,85.98,"Yes","table 3",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Abbott Alinity i SARS-CoV-2 IgG nucleocapsid","n-222",195,363,53.72,48.44,58.94,"Yes","supplementary table S2",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"Abbott Alinity SARS-CoV-2 IgG II Quant","n-198",36,37,97.3,85.84,99.93,"Yes","",TRUE,"RBD","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",1,"Abbott Architect IgG","n-96",19,38,50,33.38,66.62,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Abbott Architect IgG","n-225",149,185,80.54,74.09,85.98,"Yes","table 3",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Abbott Architect IgG","n-240",40,42,95.24,83.84,99.42,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Abbott Architect IgG","n-132",158,173,91.4,86.4,94.9,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect"
"--","South Asia","India","{ Delhi }","hospitalized + non-hospitalized patients","--","--","12/18/2020",2,"Abbott Architect IgG","n-162",527,673,78.31,75,81.36,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Abbott Architect IgG","n-215",116,166,69.88,62.29,76.75,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect"
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Abbott Architect IgG","n-108",60,62,96.77,88.83,99.61,"Yes","supplementary table 2",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Abbott Architect IgG","n-240",36,39,92.31,79.13,98.38,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Abbott Architect IgG","n-132",127,163,77.7,70.7,83.7,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect"
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Abbott Architect IgG","n-134",29,41,70.73,54.46,83.87,"Yes","figure 1",TRUE,"N","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",3,"Abbott Architect IgG","n-96",51,96,53.12,42.66,63.39,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Abbott Architect IgG","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Abbott Architect IgG","n-133",64,109,58.72,48.88,68.06,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Abbott Architect IgG","n-132",81,144,56.2,48.2,64.7,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",5,"Abbott Architect IgG","n-96",26,74,35.14,24.39,47.11,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Abbott Architect IgG","n-240",30,44,68.18,52.42,81.39,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Abbott Architect IgG","n-289",15,30,50,31.3,68.7,"Yes","figure 2g",TRUE,"N","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Abbott Architect IgG","n-132",35,107,32.8,24.2,42.3,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",7,"Abbott Architect IgG","n-96",6,23,26.09,10.23,48.41,"N","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Abbott Architect IgG","n-133",26,109,23.85,16.21,32.97,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect"
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"Abbott Architect IgG","n-198",10,37,27.03,13.79,44.12,"Yes","",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Abbott Architect IgG","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",1.5,"Abbott Architect IgG","n-89",22,24,91.67,73,98.97,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Abbott Architect IgG","n-290",186,194,95.88,92.04,98.2,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",2.5,"Abbott Architect IgG","n-89",26,29,89.66,72.65,97.81,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect"
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",3.5,"Abbott Architect IgG","n-89",16,22,72.73,49.78,89.27,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Abbott Architect IgG","n-290",106,123,86.18,78.8,91.74,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",4.5,"Abbott Architect IgG","n-89",10,14,71.43,41.9,91.61,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Abbott Architect IgG","n-290",101,162,62.35,54.4,69.83,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Abbott Architect IgG","n-290",41,95,43.16,33.03,53.72,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Abbott Architect IgG","n-290",22,89,24.72,16.19,35,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Abbott Architect IgG","n-290",18,91,19.78,12.16,29.45,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Abbott Architect IgG","n-290",5,35,14.29,4.806,30.26,"","table 1",TRUE,"N","IgG","CMIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Abingdon AbC-19 IgG anti-spike","n-213",122,152,80.26,73.04,86.27,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Abingdon AbC-19 IgG anti-spike","n-213",35,43,81.4,66.6,91.61,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Abingdon AbC-19 IgG anti-spike","n-213",50,73,68.49,56.56,78.87,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",53,57,92.98,83,98.05,"Yes","table 2",TRUE,"N","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",143,157,91.08,85.49,95.04,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",39,44,88.64,75.44,96.21,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",43,79,54.43,42.83,65.69,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Biozek COVID-19 IgG/IgM rapid test","n-213",65,68,95.59,87.64,99.08,"Yes","table 2",TRUE,"N, RBD","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Biozek COVID-19 IgG/IgM rapid test","n-213",47,49,95.92,86.02,99.5,"Yes","table 2",TRUE,"N, RBD","IgG IgM","LFIA","indirect"
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","*September 2020","--",1,"COVIDAR anti-spike anti-RBD","n-224",335,453,73.95,69.65,77.94,"Yes","table 1",TRUE,"RBD, S","IgG IgM","ELISA","indirect"
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","--","--",1,"COVIDAR anti-spike anti-RBD","n-227",252,289,87.2,82.79,90.82,"Yes","figure 1A",TRUE,"RBD, S","IgG IgM","ELISA","indirect"
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","*September 2020","--",3,"COVIDAR anti-spike anti-RBD","n-224",113,137,82.48,75.06,88.44,"Yes","table 1",TRUE,"RBD, S","IgG IgM","ELISA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Diasorin Liaison S1/S2 spike IgG","n-132",121,140,86.5,80,91.5,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Diasorin Liaison S1/S2 spike IgG","n-240",37,42,88.1,74.37,96.02,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Diasorin Liaison S1/S2 spike IgG","n-215",134,166,80.72,73.89,86.43,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect"
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Diasorin Liaison S1/S2 spike IgG","n-108",53,62,85.48,74.22,93.14,"Yes","supplementary table 2",TRUE,"S","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Diasorin Liaison S1/S2 spike IgG","n-240",36,39,92.31,79.13,98.38,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Diasorin Liaison S1/S2 spike IgG","n-134",38,41,92.68,80.08,98.46,"Yes","",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Diasorin Liaison S1/S2 spike IgG","n-132",135,166,81.6,75,87,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Diasorin Liaison S1/S2 spike IgG","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Diasorin Liaison S1/S2 spike IgG","n-133",88,109,80.73,72.07,87.66,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Diasorin Liaison S1/S2 spike IgG","n-222",295,363,81.27,76.87,85.15,"Yes","supplementary table S2",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Diasorin Liaison S1/S2 spike IgG","n-132",94,125,75.7,67.5,82.8,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Diasorin Liaison S1/S2 spike IgG","n-240",39,44,88.64,75.44,96.21,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Diasorin Liaison S1/S2 spike IgG","n-132",49,71,68.7,57.2,79.1,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Diasorin Liaison S1/S2 spike IgG","n-133",91,109,83.49,75.16,89.91,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Diasorin Liaison S1/S2 spike IgG","n-290",31,39,79.49,63.54,90.7,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Diasorin Liaison S1/S2 spike IgG","n-290",172,194,88.66,83.34,92.76,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Diasorin Liaison S1/S2 spike IgG","n-290",112,123,91.06,84.56,95.45,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Diasorin Liaison S1/S2 spike IgG","n-290",137,162,84.57,78.07,89.76,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Diasorin Liaison S1/S2 spike IgG","n-290",84,95,88.42,80.23,94.08,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Diasorin Liaison S1/S2 spike IgG","n-290",78,89,87.64,78.96,93.67,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Diasorin Liaison S1/S2 spike IgG","n-290",72,91,79.12,69.33,86.94,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Diasorin Liaison S1/S2 spike IgG","n-290",30,35,85.71,69.74,95.19,"","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"EDI Novel coronavirus COVID19 IgG anti-nucleocapsid","n-165",15,58,25.86,15.26,39.04,"Yes","",TRUE,"N","IgG","ELISA","indirect"
"1","South Asia","India","Odisha: Bhubaneswar (phase 2), Berhampur, Rourkela","representative","8/6/2020","8/31/2020","8/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-93",23,29,79.31,60.28,92.01,"Yes","table 2",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"2","South Asia","India","Odisha: Bhubaneswar","representative","--","--","8/26/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-94",2,3,66.67,9.43,99.16,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"3","South Asia","India","Odisha: Bhubaneswar","representative","--","--","9/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-94",124,132,93.94,88.41,97.35,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-225",153,185,82.7,76.47,87.86,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",147,164,89.6,84.2,93.7,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",39,42,92.86,80.52,98.5,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-108",62,62,100,94.22,100,"Yes","supplementary table 2",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",39,39,100,90.97,100,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"1","Europe","Iceland","National","convenience (general population)","4/3/2020","7/8/2020","5/21/2020",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-157",1120,1215,92.18,90.53,93.63,"Yes","tables S1 and S4, page 8 of appendix 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-134",40,41,97.56,87.14,99.94,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",150,166,90.2,85,94.2,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-222",338,363,93.11,90,95.49,"Yes","supplementary table S2",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",144,158,90.7,85.4,94.6,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",43,44,97.73,87.98,99.94,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-167",367,376,97.61,95.5,98.9,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-289",30,30,100,88.43,100,"Yes","figure 2g",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",133,146,91.1,85.7,95.1,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-165",53,58,91.38,81.02,97.14,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Sweden","{ Stockholm }","hospitalized + non-hospitalized patients","--","late 2020","--",9,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-223",31,32,96.88,83.78,99.92,"Yes","tables 2 and 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",32,39,82.05,66.47,92.46,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",193,194,99.48,97.16,99.99,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",123,123,100,97.05,100,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",160,162,98.77,95.61,99.85,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",93,95,97.89,92.6,99.74,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",84,91,92.31,84.79,96.85,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",34,35,97.14,85.08,99.93,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",35,39,89.74,75.78,97.13,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",192,194,98.97,96.33,99.87,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",123,123,100,97.05,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",162,162,100,97.75,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",95,95,100,96.19,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",88,89,98.88,93.9,99.97,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",91,91,100,96.03,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich"
"1","South Asia","India","West Bengal: Paschim Medinipur","representative","7/27/2020","8/7/2020","8/1/2020",2,"ERBALISA COVID-19 IgG","n-95",11,30,36.67,19.93,56.14,"Yes","",TRUE,"N, S","IgG","ELISA","indirect"
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"Euroimmun anti-nucleocapsid IgG IgM","n-226",77,85,90.59,82.29,95.85,"Yes","",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"Euroimmun anti-nucleocapsid IgG IgM","n-226",71,85,83.53,73.91,90.69,"Yes","",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Euroimmun anti-nucleocapsid IgG IgM","n-290",31,39,79.49,63.54,90.7,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Euroimmun anti-nucleocapsid IgG IgM","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Euroimmun anti-nucleocapsid IgG IgM","n-290",105,123,85.37,77.86,91.09,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Euroimmun anti-nucleocapsid IgG IgM","n-290",108,162,66.67,58.84,73.87,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Euroimmun anti-nucleocapsid IgG IgM","n-290",49,95,51.58,41.1,61.96,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Euroimmun anti-nucleocapsid IgG IgM","n-290",31,89,34.83,25.04,45.67,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Euroimmun anti-nucleocapsid IgG IgM","n-290",23,91,25.27,16.75,35.47,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Euroimmun anti-nucleocapsid IgG IgM","n-290",6,35,17.14,6.562,33.65,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect"
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",1,"Euroimmun anti-spike","n-170",53,54,98.15,90.11,99.95,"","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",2,"Euroimmun anti-spike","n-170",104,104,100,96.52,100,"Yes","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"Euroimmun anti-spike","n-226",83,85,97.65,91.76,99.71,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","4/6/2020","--","--",2,"Euroimmun anti-spike","n-243",113,131,86.26,79.16,91.65,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Euroimmun anti-spike","n-215",121,166,72.89,65.46,79.49,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","National (SOEP)","representative","--","--","11/11/2020",2,"Euroimmun anti-spike","n-68 , n-70",82,133,61.65,52.83,69.95,"Yes","pages 8 and 9",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","--","--",4,"Euroimmun anti-spike","n-243",113,131,86.26,79.16,91.65,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"Euroimmun anti-spike","n-226",73,85,85.88,76.64,92.49,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Euroimmun anti-spike","n-133",90,109,82.57,74.13,89.17,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Euroimmun anti-spike","n-222",280,363,77.13,72.46,81.36,"Yes","supplementary table S2",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Euroimmun anti-spike","n-289",23,30,76.67,57.72,90.07,"Yes","figure 2g",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","--","--",7,"Euroimmun anti-spike","n-243",103,131,78.63,70.61,85.3,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect"
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"Euroimmun anti-spike","n-165",40,58,68.97,55.46,80.46,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","12/17/2020","--",9,"Euroimmun anti-spike","n-243",96,131,73.28,64.85,80.63,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Euroimmun anti-spike","n-133",85,109,77.98,69.03,85.35,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Euroimmun anti-spike","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Euroimmun anti-spike","n-290",176,194,90.72,85.73,94.41,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Euroimmun anti-spike","n-290",108,123,87.8,80.68,93.01,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Euroimmun anti-spike","n-290",131,162,80.86,73.95,86.61,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Euroimmun anti-spike","n-290",75,95,78.95,69.38,86.64,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Euroimmun anti-spike","n-290",71,89,79.78,69.93,87.55,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Euroimmun anti-spike","n-290",66,91,72.53,62.17,81.37,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Euroimmun anti-spike","n-290",27,35,77.14,59.86,89.58,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"GenScript cPass neutralization kit","n-290",35,39,89.74,75.78,97.13,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"GenScript cPass neutralization kit","n-226",85,85,100,95.75,100,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"GenScript cPass neutralization kit","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"GenScript cPass neutralization kit","n-226",83,85,97.65,91.76,99.71,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"GenScript cPass neutralization kit","n-290",114,123,92.68,86.56,96.6,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"GenScript cPass neutralization kit","n-290",139,162,85.8,79.46,90.78,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"GenScript cPass neutralization kit","n-290",90,95,94.74,88.14,98.27,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"GenScript cPass neutralization kit","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"GenScript cPass neutralization kit","n-198",35,37,94.59,81.81,99.34,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"GenScript cPass neutralization kit","n-290",82,91,90.11,82.05,95.38,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"GenScript cPass neutralization kit","n-290",33,35,94.29,80.84,99.3,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive"
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"IDK (Immundiagnostik) anti-spike IgG","n-222",323,363,88.98,85.3,92.01,"Yes","supplementary table S2",TRUE,"S","IgG","ELISA","indirect"
"--","South Asia","India","{ Delhi }","hospitalized + non-hospitalized patients","--","--","12/18/2020",2,"in-house RBD ELISA (Mehdi et al.)","n-162",568,672,84.52,81.56,87.18,"N (excluded, non-commercial assay not used in a seroprevalence study)","",TRUE,"RBD","IgG","ELISA","indirect"
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*October 2020",8,"in-house THL Finland FMIA anti-spike assay","n-184",360,367,98.09,96.11,99.23,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*May 2021",13,"in-house THL Finland FMIA anti-spike assay","n-184",356,367,97,94.7,98.49,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,"S","IgG","CMIA","indirect"
"--","Europe","Finland","{ Helsinki }","convenience (general population)","--","--","--",4,"in-house THL Finland neutralization assay","n-183",63,64,98.44,91.6,99.96,"Yes","",TRUE,NA,NA,"NT (cell)",NA
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","*early November 2020","December 2020","--",7,"in-house THL Finland neutralization assay","n-182",792,867,91.35,89.28,93.14,"N","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*October 2020",8,"in-house THL Finland neutralization assay","n-184",335,367,91.28,87.91,93.96,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*May 2021",13,"in-house THL Finland neutralization assay","n-184",320,367,87.19,83.34,90.44,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"InBios SCoV-2 Detect IgG anti-spike ELISA","n-165",50,58,86.21,74.62,93.85,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",1,"Livzon COVID-19 IgG IgM lateral flow","n-105",77,216,35.65,29.27,42.43,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect"
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",2,"Livzon COVID-19 IgG IgM lateral flow","n-105",51,188,27.13,20.91,34.08,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect"
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",4,"Livzon COVID-19 IgG IgM lateral flow","n-105",9,41,21.95,10.56,37.61,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect"
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",6,"Livzon COVID-19 IgG IgM lateral flow","n-105",51,261,19.54,14.91,24.88,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect"
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",7,"Livzon COVID-19 IgG IgM lateral flow","n-105",8,41,19.51,8.821,34.87,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",52,56,92.86,82.71,98.02,"Yes","table 2",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",150,153,98.04,94.38,99.59,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",42,43,97.67,87.71,99.94,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",56,57,98.25,90.61,99.96,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA
"1","North America","USA","Hillsborough County, unvaccinated population","representative","*October 2020","*March 2021","",7,"New York, Mount Sinai RBD ELISA","n-178",25,26,96.15,80.36,99.9,"N","",TRUE,"RBD, S","IgG","ELISA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",30,32,93.75,79.19,99.23,"Yes","table 2",TRUE,"N, S","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",151,154,98.05,94.41,99.6,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",41,44,93.18,81.34,98.57,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect"
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",65,79,82.28,72.06,89.96,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect"
"1","Europe","Switzerland","{ Vaud }","convenience (general population)","5/4/2020","6/27/2020","5/31/2020",2.5,"SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)","n-301",215,219,98.17,95.39,99.5,"","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG IgA","ELISA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",1,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",25,38,65.79,48.65,80.37,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",3,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",60,96,62.5,52.03,72.18,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",5,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",44,74,59.46,47.41,70.73,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect"
"3","South Asia","India","National","representative","--","--","12/27/2020",7,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",12,23,52.17,30.59,73.18,"N","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect"
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Siemens SARS-CoV-2 Total Advia Centaur","n-134",40,41,97.56,87.14,99.94,"Yes","",TRUE,"RBD","IgG IgM","CMIA","sandwich"
"--","North America","Canada","{ Toronto and Peel }","hospitalized + non-hospitalized patients","--","--","--",2.5,"Sinai Health (Toronto) anti-spike ELISA","n-169",22,22,100,84.56,100,"Yes","figure 3",TRUE,"S","IgG","CMIA","indirect"
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-nucleocapsid IgG with AIA-CL1200","n-167",314,376,83.51,79.37,87.12,"Yes","",TRUE,"N","IgG","CMIA","indirect"
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-nucleocapsid total Ig with AIA-CL1200","n-167",365,376,97.07,94.83,98.53,"Yes","",TRUE,"N","IgG IgM IgA etc.","CMIA","sandwich"
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-spike IgG with AIA-CL1200","n-167",344,376,91.49,88.2,94.11,"Yes","",TRUE,"RBD","IgG","CMIA","indirect"
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-spike total Ig with AIA-CL1200","n-167",369,376,98.14,96.2,99.25,"Yes","",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",1,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",23,26,88.46,69.85,97.55,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",1,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-170",54,54,100,93.4,100,"Yes","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",2,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-170",107,107,100,96.61,100,"Yes","table 1",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",2,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",24,26,92.31,74.87,99.05,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",3,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",23,25,92,73.97,99.02,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",4,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",26,26,100,86.77,100,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",5,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",27,31,87.1,70.17,96.37,"Yes","",TRUE,"S","IgG","ELISA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Vitros Ortho (not total) IgG anti-spike","n-132",157,172,91,86.3,95,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Vitros Ortho (not total) IgG anti-spike","n-132",139,165,84.3,78.5,89.8,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"1","South Asia","Maldives","greater Male’ area","representative","10/15/2020","11/16/2020","10/31/2020",4,"Vitros Ortho (not total) IgG anti-spike","n-151",77,133,57.89,49.03,66.4,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Vitros Ortho (not total) IgG anti-spike","n-132",111,147,75.1,67.8,82,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Vitros Ortho (not total) IgG anti-spike","n-132",72,113,63.5,54.4,72.4,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Vitros Ortho total Ig anti-spike","n-132",86,126,68.5,60,76.5,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Vitros Ortho total Ig anti-spike","n-132",132,157,83.9,77.5,89.2,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Vitros Ortho total Ig anti-spike","n-132",139,149,93.4,88.6,96.7,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Vitros Ortho total Ig anti-spike","n-132",158,162,97.8,94.7,99.3,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Vitros Ortho total Ig anti-spike","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Vitros Ortho total Ig anti-spike","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Vitros Ortho total Ig anti-spike","n-290",118,123,95.93,90.77,98.67,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Vitros Ortho total Ig anti-spike","n-290",158,162,97.53,93.8,99.32,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Vitros Ortho total Ig anti-spike","n-290",90,95,94.74,88.14,98.27,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Vitros Ortho total Ig anti-spike","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Vitros Ortho total Ig anti-spike","n-290",88,91,96.7,90.67,99.31,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Vitros Ortho total Ig anti-spike","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich"
"1","Europe","Italy","Caldari Ortona (Villa Caldari)","representative","4/18/2020","4/19/2020","4/18/2020",1,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-107",7,7,100,59.04,100,"Yes","",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"1 - 4","Europe","Denmark","National (SSI) + 30 municipalities subset","representative","5/18/2020","12/16/2020","9/1/2020",2,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-22",217,232,93.53,89.56,96.34,"Yes","page 719",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"1","Europe","Iceland","{ National }","convenience (general population)","4/3/2020","7/8/2020","5/21/2020",3,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-157",1143,1215,94.07,92.6,95.33,"Yes","tables S1 and S4, page 8 of appendix 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"5","Europe","Denmark","National (SSI), unvaccinated population","representative","2/27/2021","4/20/2021","*3/17/2021",4,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-194",484,514,94.16,91.77,96.03,"Yes","page 4",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"6","Europe","Denmark","National (SSI), unvaccinated population","representative","5/14/2021","7/11/2021","*6/10/2021",5,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-195",282,310,90.97,87.21,93.91,"Yes","page 4",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",36,39,92.31,79.13,98.38,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",190,194,97.94,94.81,99.44,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",123,123,100,97.05,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",160,162,98.77,95.61,99.85,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",95,95,100,96.19,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",88,89,98.88,93.9,99.97,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",91,91,100,96.03,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich"
"1","Europe","Austria","Ischgl","representative","4/21/2020","4/27/2020","2020-04-24",1,"Abbott Architect IgG","n-109",99,105,94.29,87.98,97.87,NA,"table 2",FALSE,"N","IgG","CMIA","indirect"
"1","Europe","Spain","National","representative","4/27/2020","5/11/2020","2020-05-04",1,"Abbott Architect IgG","n-44",176,195,90.26,85.2,94.03,NA,"table 3",FALSE,"N","IgG","CMIA","indirect"
"1","North America","USA","Davis, Salt Lake, Summit, and Utah counties","representative","5/1/2020","6/30/2020","2020-05-31",1,"Abbott Architect IgG","n-10",25,30,83.33,65.28,94.36,NA,"",FALSE,"N","IgG","CMIA","indirect"
"1","Africa","Ethiopia","14 towns (including Addis Ababa #2)","representative","6/24/2020","7/8/2020","2020-07-01",1,"Abbott Architect IgG","n-98",30,55,54.55,40.55,68.03,NA,"",FALSE,"N","IgG","CMIA","indirect"
"2","South Asia","India","National","representative","8/17/2020","9/22/2020","2020-09-04",1,"Abbott Architect IgG","n-85",38,44,86.36,72.65,94.83,NA,"table 2 (excluded 3 samples for taken within 14 days)",FALSE,"N","IgG","CMIA","indirect"
"1","South Asia","India","Kashmir: Srinagar district","representative","10/17/2020","10/20/2020","2020-10-18",1,"Abbott Architect IgG","n-92",100,121,82.64,74.7,88.92,NA,"table 1 (1 - 4 month time interval stated on page 1795)",FALSE,"N","IgG","CMIA","indirect"
"1","South Asia","India","Kashmir (whole region)","representative","10/17/2020","11/4/2020","2020-10-26",2,"Abbott Architect IgG","n-91",140,172,81.4,74.76,86.91,NA,"176 individuals (with 4 seronegatives removed for testing earlier than 14 days)",FALSE,"N","IgG","CMIA","indirect"
"4","South Asia","India","National","representative","6/14/2021","7/6/2021","2021-06-25",2,"Abbott Architect IgG","n-97",464,782,59.34,55.8,62.8,NA,"S1 table",FALSE,"N","IgG","CMIA","indirect"
"1","Europe","Lithuania","6 cities and municipalities","representative","8/10/2020","9/10/2020","2020-08-25",4,"AMP Rapid Test SARS-CoV-2 IgG/IgM","n-172",6,12,50,21.09,78.91,NA,"",FALSE,NA,"IgG IgM","LFIA","indirect"
"--","North America","USA","{ Arkansas }","non-hospitalized patients","8/15/2020","9/5/2020","2020-08-25",1,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",10,12,83.33,51.59,97.91,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect"
"--","North America","USA","{ Arkansas }","non-hospitalized patients","9/12/2020","10/24/2020","2020-10-03",2,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",14,17,82.35,56.57,96.2,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect"
"--","North America","USA","{ Arkansas }","non-hospitalized patients","11/7/2020","12/19/2020","2020-11-28",2,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",4,8,50,15.7,84.3,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect"
"1","North America","USA","National (COVIDVu)","representative","--","--","2020-10-30",3,"BioRad Platelia Total Antibody nucleocapsid","n-143",77,127,60.63,51.57,69.18,NA,"",FALSE,"N","IgG IgM IgA","ELISA","sandwich"
"2","North America","Canada","National (CCAHS), unvaccinated population","representative","11/2/2020","4/30/2021","2021-01-30",2,"CCAHS ELISA anti-spike anti-RBD anti-nucleocapsid (positive on at least 2 out of 3)","n-261",115,145,79.31,71.8,85.58,NA,"table 1",FALSE,"N, RBD, S","IgG","CMIA","indirect"
"1","Latin America","Argentina","Puerto Madryn","representative","03/03/2021","4/17/2021","2021-03-25",5,"COVIDAR anti-spike anti-RBD","n-248",57,78,73.08,61.84,82.5,NA,"positive on nasal swab (supplemental S2 data)",FALSE,"RBD, S","IgG IgM","ELISA","indirect"
"1","South Asia","India","Puducherry: Puducherry district","representative","8/11/2020","8/16/2020","2020-08-13",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",3,3,100,29.24,100,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"2","South Asia","India","Puducherry: Puducherry district","representative","9/10/2020","9/16/2020","2020-09-13",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",3,7,42.86,9.899,81.59,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"3","South Asia","India","Puducherry: Puducherry district","representative","10/12/2020","10/16/2020","2020-10-14",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",25,29,86.21,68.34,96.11,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"1","Oceania","Indonesia","Tanjung Priok sub-district","convenience (general population)","11/23/2020","2/19/2021","2021-01-06",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-152",27,32,84.38,67.21,94.72,NA,"table 2 (excluded 17 samples for taken within 14 days)",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"1","South Asia","India","Hyderabad","representative","1/8/2021","1/24/2021","2021-01-16",4,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-101",260,298,87.25,82.92,90.82,NA,"table 2",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"2.3","East Asia","Japan","Miyagi + Osaka + Tokyo (phase 3), Aichi + Fukuoka (phase 2)","representative","12/3/2021","12/27/2021","2021-12-15",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-280",105,132,79.55,71.65,86.07,NA,"table 4 on page 6",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"3.4","East Asia","Japan","Miyagi + Osaka + Tokyo (phase 4), Aichi + Fukuoka (phase 3)","representative","2/2/2022","3/6/2022","2022-02-18",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-280",178,230,77.39,71.43,82.63,NA,"table 4 on page 6",FALSE,"N","IgG IgM IgA","CMIA","sandwich"
"3","South Asia","India","Delhi","representative","9/1/2020","9/7/2020","2020-09-04",2,"ERBALISA COVID-19 IgG","n-83",148,226,65.49,58.9,71.67,NA,"",FALSE,"N, S","IgG","ELISA","indirect"
"4","South Asia","India","Delhi","representative","10/15/2020","10/21/2020","2020-10-18",2,"ERBALISA COVID-19 IgG","n-83",147,260,56.54,50.28,62.65,NA,"",FALSE,"N, S","IgG","ELISA","indirect"
"1","Europe","Austria","Ischgl","representative","4/21/2020","4/27/2020","2020-04-24",1,"Euroimmun anti-spike","n-109",98,105,93.33,86.75,97.28,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","France","National","representative","--","--","2020-05-21",3,"Euroimmun anti-spike","n-149",74,83,89.16,80.41,94.92,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","France","Grand Est, Île-de-France, Nouvelle-Aquitaine","representative","5/4/2020","6/23/2020","2020-05-29",1,"Euroimmun anti-spike","n-31",68,78,87.18,77.68,93.68,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Kupferzell","representative","5/20/2020","6/9/2020","2020-05-30",2,"Euroimmun anti-spike","n-110 , n-295",43,50,86,73.26,94.18,NA,"table 3",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Bad Feilnbach","representative","6/23/2020","7/4/2020","2020-06-28",3,"Euroimmun anti-spike","n-295",22,42,52.38,36.42,68,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect"
"1","South Asia","India","Pune (five prabhags/subwards)","representative","7/20/2020","8/5/2020","2020-07-28",1,"Euroimmun anti-spike","n-84",19,21,90.48,69.62,98.83,NA,"tables 1 and 2",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Reutlingen district","representative","7/1/2020","7/28/2020","2020-07-14",3,"Euroimmun anti-spike","n-26",10,11,90.91,58.72,99.77,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Freiburg + Breisgau-Hochschwarzwald","representative","8/5/2020","9/1/2020","2020-08-18",5,"Euroimmun anti-spike","n-26",12,16,75,47.62,92.73,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Straubing","representative","9/8/2020","9/26/2020","2020-09-17",5,"Euroimmun anti-spike","n-295 , n-234",17,32,53.12,34.74,70.91,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Aachen","representative","9/9/2020","10/9/2020","2020-09-24",6,"Euroimmun anti-spike","n-26",9,14,64.29,35.14,87.24,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect"
"2","Europe","Germany","Reutlingen district","representative","10/14/2020","11/10/2020","2020-10-27",6,"Euroimmun anti-spike","n-26 , n-173",17,21,80.95,58.09,94.55,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Osnabrück district + Osnabrück city","representative","10/15/2020","11/15/2020","2020-10-30",3,"Euroimmun anti-spike","n-26",11,17,64.71,38.33,85.79,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Mitte (in Berlin)","representative","11/17/2020","12/5/2020","2020-11-26",1,"Euroimmun anti-spike","n-295 , n-236",21,35,60,42.11,76.13,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect"
"2","Europe","Germany","Freiburg + Breisgau-Hochschwarzwald","representative","11/18/2020","12/15/2020","2020-12-01",2,"Euroimmun anti-spike","n-26 , n-173",10,11,90.91,58.72,99.77,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Magdeburg","representative","11/18/2020","12/15/2020","2020-12-01",1,"Euroimmun anti-spike","n-26",26,28,92.86,76.5,99.12,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect"
"2","Europe","Germany","Aachen region, unvaccinated population","representative","1/25/2021","2/27/2021","2021-02-10",3,"Euroimmun anti-spike","n-26 , n-173",61,70,87.14,76.99,93.95,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect"
"2","Europe","Germany","Osnabrück district + Osnabrück city, unvaccinated population","representative","3/1/2021","3/31/2021","2021-03-16",3,"Euroimmun anti-spike","n-26 , n-173",34,37,91.89,78.09,98.3,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect"
"2","Europe","Germany","Magdeburg, unvaccinated population","representative","4/7/2021","5/5/2021","2021-04-21",3,"Euroimmun anti-spike","n-26 , n-173",33,40,82.5,67.22,92.66,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect"
"1.2","Europe","Germany","Chemnitz, unvaccinated population","representative","3/3/2021","8/17/2021","2021-05-25",5,"Euroimmun anti-spike","n-173",220,257,85.6,80.71,89.66,NA,"eSupplement-Table 3",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Germany","Vorpommern-Greifswald, unvaccinated population","representative","5/12/2021","6/8/2021","2021-05-25",3,"Euroimmun anti-spike","n-173",70,86,81.4,71.55,88.98,NA,"eSupplement-Table 3",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","England","National (REACT-2)","representative","6/20/2020","7/13/2020","2020-07-01",2,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-14",277,341,81.23,76.68,85.24,NA,"supplemental table 3",FALSE,"S","IgG IgM","LFIA","indirect"
"2","Europe","England","National (REACT-2)","representative","7/31/2020","8/13/2020","2020-08-06",3,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-102",274,360,76.11,71.36,80.42,NA,"supplemental table S3 in file 7",FALSE,"S","IgG IgM","LFIA","indirect"
"3","Europe","England","National (REACT-2)","representative","9/15/2020","9/28/2020","2020-09-21",4,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-102",474,750,63.2,59.64,66.66,NA,"supplemental table S3 in file 7",FALSE,"S","IgG IgM","LFIA","indirect"
"4","Europe","England","National (REACT-2)","representative","10/27/2020","11/10/2020","2020-11-03",1,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-15",1094,1765,61.98,59.67,64.25,NA,"table S2",FALSE,"S","IgG IgM","LFIA","indirect"
"1","Europe","Spain","Cantabria","representative","4/27/2020","5/29/2020","2020-05-13",1,"Hangzhou Clongene IgM/IgG rapid test","n-46",2,3,66.67,9.43,99.16,NA,"table 1, used only IgG",FALSE,NA,"IgG","LFIA","indirect"
"1","Africa","South Africa","Gauteng","representative","11/4/2020","1/22/2021","2020-12-13",5,"in-house Luminex S protein trimer IgG","n-99",57,122,46.72,37.64,55.97,NA,"",FALSE,"RBD","IgG","CMIA",NA
"1","Africa","Tunisia","El Omrane + La Goulette","representative","*March 2021","*April 2021","2021-04-01",3,"in-house ELISA for N protein and S protein from IPT (Institut Pasteur in Tunis)","n-196",56,73,76.71,65.35,85.81,NA,"table 3",FALSE,"N, RBD","IgG","ELISA",NA
"2","South Asia","India","Delhi","representative","8/1/2020","8/7/2020","2020-08-04",1,"Kavach-AntiSARS-CoV-2 IgG ELISA (Zydus)","n-83",232,356,65.17,59.97,70.11,NA,"",FALSE,"N, RBD, S","IgG","ELISA","indirect"
"1","Europe","Andorra","National","representative","5/4/2020","5/13/2020","2020-05-08",1,"Livzon COVID-19 IgG IgM lateral flow","n-43",305,378,80.69,76.34,84.55,NA,"",FALSE,NA,"IgG IgM","LFIA","indirect"
"2","Europe","USA","Los Angeles County, unvaccinated population","representative","4/9/2021","4/25/2021","2021-04-17",4,"Luminex xMAP for spike and nucleocaspid (Los Angeles study used RBD portion)","n-174",57,59,97,90.3,99.1,NA,"table 2",FALSE,"RBD","IgG","CMIA","indirect"
"1","Europe","USA","Holyoke","representative","11/5/2020","12/31/2020","2020-12-03",2,"Massachusetts General Hospital, anti-spike ELISA","n-78",12,18,66.67,40.99,86.66,NA,"figure 2C",FALSE,"RBD","IgG","ELISA","indirect"
"1","Europe","USA","Hillsborough County, unvaccinated population","representative","*October 2020","*March 2021","2021-01-01",4,"New York, Mount Sinai RBD ELISA","n-178",122,126,96.83,92.07,99.13,NA,"appendix table",FALSE,"RBD, S","IgG","ELISA","indirect"
"1","Europe","Spain","National","representative","4/27/2020","5/11/2020","2020-05-04",1,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-44",189,213,88.73,83.7,92.65,NA,"table 2",FALSE,"S","IgG IgM","LFIA","indirect"
"2","Europe","Spain","National","representative","5/18/2020","6/1/2020","2020-05-25",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-104",276,360,76.67,71.95,80.94,NA,"tabla 6 (page 19)",FALSE,"S","IgG IgM","LFIA","indirect"
"3","Europe","Spain","National","representative","6/8/2020","6/22/2020","2020-06-15",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-104",341,460,74.13,69.87,78.07,NA,"tabla 6 (page 19)",FALSE,"S","IgG IgM","LFIA","indirect"
"4","Europe","Spain","National","representative","11/16/2020","11/29/2020","2020-11-22",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-45",1137,1777,63.98,61.7,66.22,NA,"tabla 8 (page 20)",FALSE,"S","IgG IgM","LFIA","indirect"
"1","Europe","Switzerland","11 cantons","representative","*October 2020","*February 2021","2020-12-20",1,"SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)","n-299",128,143,89.51,83.29,94.01,NA,"table 1 (not yet in seroreversion paper nor in PRISMA list / tab)",FALSE,"S","IgG IgA","ELISA","indirect"
"1","Europe","Portugal","National (Castro et al.)","convenience (general population)","9/8/2020","10/14/2020","2020-09-26",3,"Siemens SARS-CoV-2 Total Advia Centaur","n-155",112,136,82.35,74.89,88.35,NA,"appendix 11",FALSE,"RBD","IgG IgM","CMIA","sandwich"
"1","Latin America","Peru","Lima Metropolitana (provinces of Lima + Callao)","representative","6/28/2020","7/9/2020","2020-07-03",1,"Standard Q COVID-19 IgM/IgG Plus","k-15",77,84,91.67,83.58,96.58,NA,"table S9",FALSE,"N, RBD","IgG IgM","LFIA","indirect"
"1","Middle East","Lebanon","National","representative","12/7/2020","1/15/2021","2020-12-26",2,"Techno Genetics anti-RBD, nCOVID-19 IgG/IgM POCT (point-of-care test)","n-150",38,60,63.33,49.9,75.41,NA,"table 3",FALSE,"RBD","IgG IgM","LFIA","indirect"
"1","North America","USA","Connecticut","representative","6/10/2020","7/29/2020","2020-07-04",2,"Vitros Ortho (not total) IgG anti-spike","n-2",11,11,100,71.51,100,NA,"table 3",FALSE,"S","IgG","CMIA","indirect"
"5","South Asia","India","Delhi, unvaccinated population","representative","1/11/2021","1/22/2021","2021-01-16",3,"Vitros Ortho (not total) IgG anti-spike","n-86",817,1121,72.88,70.18,75.47,NA,"table 2",FALSE,"S","IgG","CMIA","indirect"
"6","South Asia","India","Delhi, unvaccinated population","representative","9/24/2021","10/14/2021","2021-10-04",6,"Vitros Ortho (not total) IgG anti-spike","n-153",1739,2143,81.15,79.43,82.78,NA,"table 4",FALSE,"S","IgG","CMIA","indirect"
